355 related articles for article (PubMed ID: 28257090)
21. Hypoxia-dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression.
Hirschfeld M; Zhang B; Jaeger M; Stamm S; Erbes T; Mayer S; Tong X; Stickeler E
Mol Carcinog; 2014 Nov; 53(11):883-92. PubMed ID: 23765422
[TBL] [Abstract][Full Text] [Related]
22. Alternative splicing as a biomarker and potential target for drug discovery.
Le KQ; Prabhakar BS; Hong WJ; Li LC
Acta Pharmacol Sin; 2015 Oct; 36(10):1212-8. PubMed ID: 26073330
[TBL] [Abstract][Full Text] [Related]
23. Alternative transcription and alternative splicing in cancer.
Pal S; Gupta R; Davuluri RV
Pharmacol Ther; 2012 Dec; 136(3):283-94. PubMed ID: 22909788
[TBL] [Abstract][Full Text] [Related]
24. Leukocyte common antigen-related tyrosine phosphatase receptor: increased expression and neuronal-type splicing in breast cancer cells and tissue.
Yang T; Zhang JS; Massa SM; Han X; Longo FM
Mol Carcinog; 1999 Jun; 25(2):139-49. PubMed ID: 10365916
[TBL] [Abstract][Full Text] [Related]
25. Aberrant and alternative splicing in skeletal system disease.
Fan X; Tang L
Gene; 2013 Oct; 528(1):21-6. PubMed ID: 23800666
[TBL] [Abstract][Full Text] [Related]
26. Aberrant and alternative splicing in cancer.
Venables JP
Cancer Res; 2004 Nov; 64(21):7647-54. PubMed ID: 15520162
[TBL] [Abstract][Full Text] [Related]
27. The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers.
Cohen-Eliav M; Golan-Gerstl R; Siegfried Z; Andersen CL; Thorsen K; Ørntoft TF; Mu D; Karni R
J Pathol; 2013 Mar; 229(4):630-9. PubMed ID: 23132731
[TBL] [Abstract][Full Text] [Related]
28. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.
Sun L; Goodman PA; Wood CM; Crotty ML; Sensel M; Sather H; Navara C; Nachman J; Steinherz PG; Gaynon PS; Seibel N; Vassilev A; Juran BD; Reaman GH; Uckun FM
J Clin Oncol; 1999 Dec; 17(12):3753-66. PubMed ID: 10577847
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
30. Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy.
Salton M; Misteli T
Trends Mol Med; 2016 Jan; 22(1):28-37. PubMed ID: 26700537
[TBL] [Abstract][Full Text] [Related]
31. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.
David CJ; Manley JL
Genes Dev; 2010 Nov; 24(21):2343-64. PubMed ID: 21041405
[TBL] [Abstract][Full Text] [Related]
32. Misregulation of pre-mRNA alternative splicing in cancer.
Zhang J; Manley JL
Cancer Discov; 2013 Nov; 3(11):1228-37. PubMed ID: 24145039
[TBL] [Abstract][Full Text] [Related]
33. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene.
Watermann DO; Tang Y; Zur Hausen A; Jäger M; Stamm S; Stickeler E
Cancer Res; 2006 May; 66(9):4774-80. PubMed ID: 16651431
[TBL] [Abstract][Full Text] [Related]
34. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis.
Stickeler E; Kittrell F; Medina D; Berget SM
Oncogene; 1999 Jun; 18(24):3574-82. PubMed ID: 10380879
[TBL] [Abstract][Full Text] [Related]
35. Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.
Tschan MP; Federzoni EA; Haimovici A; Britschgi C; Moser BA; Jin J; Reddy VA; Sheeter DA; Fischer KM; Sun P; Torbett BE
Biochim Biophys Acta; 2015 Sep; 1849(9):1198-208. PubMed ID: 26187004
[TBL] [Abstract][Full Text] [Related]
36. Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors.
Bordeleau F; Califano JP; Negrón Abril YL; Mason BN; LaValley DJ; Shin SJ; Weiss RS; Reinhart-King CA
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8314-9. PubMed ID: 26106154
[TBL] [Abstract][Full Text] [Related]
37. Aberrant alternative splicing in breast cancer.
Yang Q; Zhao J; Zhang W; Chen D; Wang Y
J Mol Cell Biol; 2019 Oct; 11(10):920-929. PubMed ID: 31065692
[TBL] [Abstract][Full Text] [Related]
38. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
39. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.
Adamia S; Kriangkum J; Belch AR; Pilarski LM
Adv Cancer Res; 2014; 123():67-94. PubMed ID: 25081526
[TBL] [Abstract][Full Text] [Related]
40. Relative expression of hMena11a and hMenaINV splice isoforms is a useful biomarker in development and progression of human breast carcinoma.
Tanaka N; Yoshida H; Suzuki Y; Harigaya K
Int J Oncol; 2014 Nov; 45(5):1921-8. PubMed ID: 25109497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
